{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=34", "query": { "intervention": "Combination 400", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 1062, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T21:56:34.851Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04204941", "title": "Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Soft-tissue Sarcoma", "Advanced Epithelioid Sarcoma" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Doxorubicin HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2019-12-19", "completion_date": "2024-06-14", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 18, "location_summary": "Duarte, California • Santa Monica, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04204941" }, { "nct_id": "NCT03742245", "title": "Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer Metastatic", "Breast Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-06-11", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03742245" }, { "nct_id": "NCT00599131", "title": "Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer of Larynx" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2007-08", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00599131" }, { "nct_id": "NCT00069095", "title": "A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oxaliplatin 130 mg/m^2", "type": "DRUG" }, { "name": "Capecitabine 1000 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 7.5 mg/kg", "type": "DRUG" }, { "name": "Placebo for bevacizumab 7.5 mg/kg", "type": "DRUG" }, { "name": "Oxaliplatin 85 mg/m^2", "type": "DRUG" }, { "name": "Leucovorin 200 mg/m^2", "type": "DRUG" }, { "name": "Fluorouracil 400 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 5 mg/kg", "type": "DRUG" }, { "name": "Placebo for bevacizumab 5 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2035, "start_date": "2003-07", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2016-10-06", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 49, "location_summary": "Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069095" }, { "nct_id": "NCT01662869", "title": "A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "5-Fluoruracil", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" }, { "name": "Onartuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 564, "start_date": "2012-11", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 15, "location_summary": "Los Angeles, California • Denver, Colorado • Fort Myers, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01662869" }, { "nct_id": "NCT00835679", "title": "Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Liver Metastases", "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2009-12", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-05-23", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 2, "location_summary": "Tampa, Florida • Nashville, Tennessee", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00835679" }, { "nct_id": "NCT01433991", "title": "A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Golvatinib", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2011-10-13", "completion_date": "2017-03-01", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01433991" }, { "nct_id": "NCT00981318", "title": "Pilot Assessment of Lopinavir/Ritonavir and Maraviroc", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections", "Acquired Immunodeficiency Syndrome" ], "interventions": [ { "name": "lopinavir/ritonavir plus maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rodwick, Barry M., M.D.", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2009-12", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2015-06-23", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 1, "location_summary": "Safety Harbor, Florida", "locations": [ { "city": "Safety Harbor", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00981318" }, { "nct_id": "NCT01542788", "title": "Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "Placebo to match SOF", "type": "DRUG" }, { "name": "Placebo to match RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 278, "start_date": "2012-03", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-05-19", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01542788" }, { "nct_id": "NCT00544817", "title": "Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2007-04", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2016-09-01", "last_synced_at": "2026-11-08T21:56:34.851Z", "location_count": 10, "location_summary": "Fort Myers, Florida • Gainesville, Georgia • Bethesda, Maryland + 7 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544817" } ] }